ChromaDex - CDXC Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDXC shares.
View CDXC analyst ratings or view top-rated stocks.

4 brokers have issued 12 month price objectives for ChromaDex's stock. Their CDXC share price forecasts range from $2.10 to $7.00. On average, they expect the company's share price to reach $5.40 in the next twelve months. This suggests a possible upside of 158.4% from the stock's current price.
View analysts price targets for CDXC or view top-rated stocks among Wall Street analysts.

ChromaDex's stock was trading at $1.68 on January 1st, 2023. Since then, CDXC shares have increased by 24.4% and is now trading at $2.09.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our CDXC earnings forecast.

ChromaDex Co. (NASDAQ:CDXC) released its earnings results on Tuesday, November, 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.04. The company earned $17.31 million during the quarter, compared to analyst estimates of $17.18 million. ChromaDex had a negative net margin of 29.71% and a negative trailing twelve-month return on equity of 90.73%. During the same quarter in the prior year, the company posted ($0.07) EPS.

13 employees have rated ChromaDex Chief Executive Officer Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among the company's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 46.0% of employees surveyed would recommend working at ChromaDex to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other ChromaDex investors own include Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), ADMA Biologics (ADMA), Athersys (ATHX), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Tilray (TLRY), Dynavax Technologies (DVAX), Glu Mobile (GLUU) and Great Panther Mining (GPL).

ChromaDex trades on the NASDAQ under the ticker symbol "CDXC."

ChromaDex's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cowen Prime Advisors LLC (0.10%), International Assets Investment Management LLC (0.03%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Frank L Jaksch Jr, Hoi Shuen Solina Holly Chau, Kevin M Farr, Robert N Fried and Stephen A Block.
View institutional ownership trends.

Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDXC stock can currently be purchased for approximately $2.09.

ChromaDex (NASDAQ:CDXC) has a market capitalization of $155.64 million and generates $67.45 million in revenue each year. The company earns $-27,130,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

The company employs 115 workers across the globe.

ChromaDex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The official website for the company is www.chromadex.com. The company can be reached via phone at (310) 388-6706, via email at investorrelations@chromadex.com, or via fax at 949-419-0294.